Risk of relapse to binge eating disorder lower for lisdexamfetamine compared with placebo

Patients with binge eating disorder (BED) who were randomized to lisdexamfetamine dimesylate after initial response to the drug in an open‐label trial had a significantly lower risk of relapse than patients randomized to placebo, a study has found. Most adverse effects from lisdexamfetamine were mild to moderate in severity and were in line with the drug's safety profile from prior BED studies and from trials in treating attention‐deficit hyperactivity disorder (ADHD), the researchers reported.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: What's New in Research Source Type: research